Resistant and severe hypertension represent a growing global health burden and are associated with a markedly increased risk of cardiovascular, renal, and ...

As the cells differentiated, they expressed even higher levels of genes involved in aldosterone synthesis and became increasingly active. "The identification of two distinct cell fates in APAs ...

Hypertension is an important public health problem affecting more than 50 million individuals in the US alone. The most common form, essential hypertension, results from the complex interplay between ...

Current treatment options for primary aldosteronism are limited to surgery or mineralocorticoid receptor antagonists when surgery isn't an option. In a phase IIa trial, baxdrostat resolved or reduced ...

Lorundrostat treatment led to greater reductions in 24-hour mean blood pressure compared with placebo in trial participants with uncontrolled and treatment-resistant hypertension. Lorundrostat, a ...

Single-nucleus RNA sequencing of 2 nonfunctional adenomas and 3 aldosterone-producing adenomas revealed 13 clusters (Upper). Pseudotime course analysis predicted the transition of two cell fates in ...

The data from the Launch-HTN trial, announced at the 34th European Meeting on Hypertension and Cardiovascular Protection, show that lorundrostat, an aldosterone synthase inhibitor, is a safe and ...